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he genomics revolution, which has seemingly
pervaded all of the biological and biomedical
sciences, has brought about its most impressive
advances in the pharmaceutical sciences. The
technological advances in high-throughput
DNA sequencing, in assessing gene expression
for thousands of transcripts, and in RNA construFcts to silence specific genes have not only
been the driving force behind genomic studies, but have also
contributed to an emerging paradigm shift that is occurring
in pharmacology, drug development, and pharmacotherapeutics. The molecular tools now readily available to laboratories have hastened the shift from drug development based
largely on chemistry to one based on our growing biological knowledge of the physiological and molecular effects of
compounds.1 It is now becoming possible with these tools to
assess at the cellular level the nature of drug action, toxicity,
and tolerance. Similarly, our understanding of human disease
is being refined, which will lead to more precise therapeutic
interventions based on more precise understandings of disease states.
Ironically, the area of genomic-driven advances in pharmacy that enjoys the most public press is also the area where
the advances are the least certain. Much has been written
about the age of personalized medicine where each patient’s
genetic makeup will determine an individual-specific course of
drug treatment designed to be the most efficacious and safe.
Pharmacogenetics, which has been an active area of research
for over 50 years,2 seeks to provide patients efficacious therapeutics with minimal adverse drug reactions based on their
genetic makeup (genotype) at one or more genes determining
drug metabolism and/or drug transport (drug metabolism or
transport pharmacogenetics) or in genes that are the direct
targets of drug action (drug target pharmacogenetics). The
literature is extensive, including several new journals detailing
studies showing gene-drug relationships and the importance
of including a patient’s genetic makeup in guiding therapeutic
decision making.3-7 However, a significant portion of this
body of literature consists of contradictory reports or at the
least call into question the utility of genetic testing in guiding therapeutic management. For example, one of the most
studied genes in pharmacogenetics, MDR1 (ABCB1), the gene
that codes for the ubiquitous drug efflux pump, P-glycoprotein (P-gp), has so far defied any straightforward consensus
concerning the importance of genetic polymorphisms in drug
disposition and response.8 Regarding the pharmacogenetics of
cytochrome P450 genes (CYP), Nebert and Vesell9 have cautioned that even recent, much lowered estimates of reductions
in adverse drug reactions of 10% to 20% by the extensive
genotyping of CYP polymorphisms may be overly optimistic.
This constant background of contrary data suggests caution
should be used in assessing the importance of pharmacogenetics in managing drug therapies.10-14
The many contrary reports, or the authors making them,
are not suggesting that there is little to be gained by pharmacogenetics studies and genetic testing. Rather, this data underscores the complexity of the human genome, the extensive
genetic diversity among humans, and the nature of gene-gene
and gene-environment interactions. This paper summarizes
some of these complexities using two of the more successful
pharmacogenetic “stories” to highlight the confounding issues involved for all genes that play a role in drug response
and efficacy.
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Prior to considering the complexities of genomes, it is
first important to reaffirm the role of environmental factors
in individual variation of drug response. There are many
environmental factors determining how a given patient will
respond to a drug including age, gender, diet, as well other
concurrent drug therapies (Figure 1). These nongenetic factors
often play a large role in the discrepancies in genotype-phenotype studies.13 Assessing the proportion of variation in patient
response due to environment is absolutely essential before the
role of genetics can be considered.

Figure 1_Many factors, both environmental, patient-specific, and
genetic may determine how an individual will respond to a therapeutic agent. Pharmacogenetics seeks to identify that portion of variation
in response due to genetic differences among humans.

The two pharmacogenetic “success stories” that follow
are in part successful because the involved compounds possess two critical properties. These properties are shared by
most pharmacogenetics success stories.9 The first property is
one born of the drug itself. Drugs with narrow therapeutic
windows are more likely to be pharmacogenetically relevant
since even small, genetically-based differences in patient drug
metabolism, absorption, distribution, or clearence may result
in toxicity. Second, for both groups of compounds there exists at least one critical step in the drug response pathway
controlled principally by a single gene—the phenotype is
said to be monogenic. Drugs that are metabolized by many
genes, or for which there are multiple alternate pathways, are
unlikely to elicit varying responses due to polymorphisms in a
single gene—the phenotype is said to be polygenic. Similarly,
in the same sense that multiple genes lessen the importance
of any one gene in patient response, multiple polymorphisms
within one gene will tend to lessen the utility of pharmacogenetic studies. The pharmacogenetics of a system can become
confusing if the gene responsible for the phenotype has many
polymorphisms, all with the similar phenotypic outcomes (referred to as allelic heterogeneity). In such cases, the utility of a
single genetic test to guide dosing is small if it is predictive for
only a limited subset of patients.
The two examples described here are the pharmacogenetics of thiopurines and warfarin. These compounds both have
narrow therapeutic windows and have phenotypes that are
determined by one or two genes. They have both been noted
repeatedly as classic examples of the important role pharmacogenetics will play in explaining variation in patient response.
labmedicine.com

Feature
We will use them here to elucidate other features of both
drugs and genetics that are important in understanding the
limitations and complexities of pharmacogenetics.

Pharmacogenetics of Thiopurine
S-methyltransferase (TPMT)
Thiopurines are among the first line treatments for childhood acute lymphoblastic leukemia (ALL), organ transplant
recipients, inflammatory bowel disease, and autoimmune
diseases.14 Thiopurine S-methyltransferase catalyzes the Smethylation of a number of chemotherapeutic prodrugs such
as 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), and azathiopurine (AZA). In the cell, 6-MP and AZA are converted
into thioinosine monophosphate (TIMP) and ultimately into
thioguanosine monophosphate (TGMP). TGMP is ultimately
converted into cytotoxic nucleotide analogs (TGN), which inhibits DNA and RNA synthesis. The S-methylation of 6-MP
to methylmercaptopurine (meMP) is an inactivation pathway
leading to the ultimate clearance of 6-MP and 6-TG (Figure
2). High TGN accumulation has been linked to hematopoietic toxicity and results in low patient tolerance to thiopurine
therapy. The genetic role of polymorphisms in TPMT and
resulting enzyme activity was first noted in red blood cells of
healthy volunteers.16 Three groups were indentified with high,
intermediate, and low enzyme activities. These three groups

have now been shown to represent individuals carrying either
zero, one, or two variant alleles for TPMT. Thus, hematopoietic toxicity, the phenotype of interest, is determined in part
by a single gene (monogenic). Interestingly, another enzyme,

Figure 2_The inactive prodrugs, 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), and azathioprine (AZA), are activated by multiple enzymes.
After uptake, 6-MP and AZA are converted into thioinosine monophosphate (TIMP). 6-TG is converted into thioguanosine monophosphate
(TGMP). Thiopurine methyltransferase (TPMT) is the major enzyme involved in the inactivation pathway for all three thiopurines to methylmercaptopurine (meMP), 6-methylmercaptopurine (6-meMPR), methyl-thioguanosine monophosphate (meTGMP), and methy-thioinosine
monophosphate (meTIMP). Cytotoxic effects of thiopurine drugs occur when cytotoxic nucleotide analogs (TGN) are incorporated into DNA
or RNA stopping synthesis. Adapted from www.pharmgkb.org/index.jsp.15
labmedicine.com
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xanthine oxidase (XHD), also plays a role in inactivation of
thiopurines. However, in hematopoietic tissue, XHD is not
expressed17 so the polymorphisms that must certainly exist in
XDH do not confound the phenotypic response of interest;
namely, hematopoietic toxicity.
Polymorphisms in TPMT have been shown to play a
role in explaining individual variation in response to thiopurine drug therapy. Low TPMT activity is associated with
hematopoietic toxicity in patients treated with standard
doses of 6-MP, 6-TG, or AZA.18 Twenty-nine variant alleles have been identified in TPMT as of 2008. Of these
variant alleles, four have been most studied (for review see
Wang and Weinshilboum19) with regard to their effects on
decreased TPMT activity—TPMT*2, *3A (most common in
Caucasians), *3B, and *3C (most common variant in African
Americans). The most common variant allele, TPMT*3A,
is associated with low TPMT activity though no differences

are noted in gene expression compared with the wildtype
allele.20 TPMT*2 shows loss of catalytic activity though no
difference in mRNA concentrations.21 The low enzyme activity observed for both variants is likely due to greater rate of
degradation.20,22 Most importantly, while other variants have
been identified (TMPT*4, *5, *6, and *7), they appear to be
rare and therefore unlikely to confound the relationship between phenotype and genotype, at least among the populations studied to date. Note, however, that the four common
variant alleles do not explain all the side effects associated
with thiopurine therapy.23 As is often the problem for many
other pharmacogenetic cases, there are other variant alleles
264
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for TPMT whose frequencies and, therefore, importance in
other populations is yet unknown. In a review examining the
role of genetic variation in TPMT mediated adverse drug reactions, van Aken and colleagues found that 78% of the adverse drug reactions could not be accounted for by a limited
number of polymorphisms generally examined in TPMT.23
These authors point out the need for further studies identifying additional variant alleles in other ethnic groups and for
the need for continued careful clinical monitoring of adverse
drug reactions.

Pharmacogenetics of Warfarin
Warfarin is a commonly prescribed oral anticoagulant
for the prevention and treatment of myocardial infarction,
ischemic stroke, venous thrombosis, and atrial fibrillation.
Warfarin has a narrow therapeutic window with large interpatient variation. Insufficient dosing may prevent thromboembolism while over dosing may cause risk of bleeding
events. Warfarin is a very effective antagonist of the vitamin
K epoxide reductase complex (VKORC1), a critical enzyme
in the vitamin K-dependent clotting pathway. Warfarin is
delivered as a racemic mixture of the R and S stereoisomers.
The stereoisomers are metabolized by different members
of the cytochrome P450 phase 1 enzymes. S-warfarin is
the more potent inhibitor of VKORC1 by 3- to 5-fold and
accounts for 60% to 70% of the anticoagulation response
(for review see Yin and Miyata24). This is critical in terms
of warfarin’s pharmacogenetics since S-warfarin is largely
metabolized by a single enzyme (CYP2C9) and thus behaves
as a monogenic trait. In contrast, R-warfarin is metabolized
by a number of CYP enzymes, mainly CYP3A4, and to a
lesser degree CYP 1A1, 1A2, 2C8, 2C9, 2C18, and 2C19.
If R-warfarin were the most active agent, it is unlikely this
drug would be important pharmacogenetically since with
so many different genes involved in its metabolism, no single
set of polymorphisms would be useful predictors of therapeutic outcome.
To date, more than 50 variants in CYP2C9 have been
described in human populations; at least 24 are nonsynonymous substitutions resulting in proteins with altered amino
acids sequences. Two variants, CYP2C9*2 and *3, are the
most common and most extensively studied. Patients with
CYP2C9*2 and/or CYP2C9*3 variants metabolize warfarin
more slowly; thus, traditional dosing regimens may lead to
bleeding events or longer times to achieve stable drug concentrations versus dose during which bleeding events may
occur. Other polymorphisms that occur at much lower frequencies have not been evaluated. Importantly, frequencies of
CYP2C9*2 and *3 vary considerably among ethnic populations. Among Caucasians, *2 and *3 frequencies vary from
8% to 20% and 6% to 10%, respectively. Unfortunately, in
respect to their utility as general predictors of patient response
to warfarin therapy, CYP2C9*2 and *3 are largely absent in
Asian populations and are rare in African-American populations with frequencies ranging from 1% to 4%. Once again,
the distribution of clinically important alleles among human
populations is important and limits the universal application
of data gathered from one ethnic group. This problem cannot
be overstated. The advancements to be derived from pharmacogenetics are dependent upon the cataloging of all relevant
variants in human populations and the development of largescale genetic screening technologies to identify these alleles.
labmedicine.com
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Figure 3_Warfarin is a natural product and is given as a racemic mixture of the R and S stereoisomers of the drug. The stereoisomers are
metabolized by a number of phase 1 enzymes, though significantly the S isomer is metabolized by a single enzyme, CYP2C9. In contrast, the
less active R-warfarin is metabolized mainly by CYP3A4, but also CYP1A1, CYP1A2, CYP2C8, CYP2C9, CYP2C18, and CYP2C19. Warfarin, particularly the S isomer, is a potent inhibitor of vitamin K epoxide reductase complex (VKORC1), a critical enzyme in the vitamin K-dependent
clotting pathway. Adapted from www.pharmgkb.org/index.jsp.15

There is yet another player in the warfarin pharmacogenetics story. The target of warfarin (VKORC1) also has
variant alleles that affect how patients respond to therapy.
This is an example of drug target pharmacogenetics, which,
unlike pharmacogenetics of genes involved in drug metabolism or drug transport, often results in differences in the
pharmacodynamics of response. Mutations in VKORC1 have
been identified in vitamin K-deficiency disorders and warfarin resistance. There are at least five important variants for
VKORC1 as well as numerous, less-common variants. Fortunately, these variants can be grouped into four haplotypes—
chromosomal segments within which the DNA sequence
is invariant or constant among most human populations.
These four haplotypes (VKORC1*1, *2, *3, and *4) include
most of the common SNPs that contribute to interpatient
variation in warfarin dosing in Caucasians. VKORC1*1 is
considered the reference sequence and is the likely ancestral
haplotype. Individuals with the VKORC1*2 haplotype (also
confusingly referred to as haplotype group A) require lower
warfarin doses. This haplotype is common in Asians and
Caucasians and rare in African populations.25 VKORC1*3
and VKORC1*4 (referred to as haplotype group B) require
a higher warfarin dose. VKORC1*3 is the most common
haplotype in African populations and is also common in
Caucasians.
Recently, another CYP gene has been identified that
has a clinically important impact on the ability of patients to
reach stable warfarin dosing. An allele in CYP4F2 that is at
moderate frequency in Asians and Caucasians (~30%) though
labmedicine.com

low in African-Americans (7%) results in higher warfarin
doses to stable dosing. Thus, the warfarin story becomes less
perfect. The metabolic role of CYP4F2 is, as yet, unknown.

Summary
Neither of the two examples presented here is the perfect
pharmacogenetics story, though they may be the best examples
to date. Our goal is to highlight these two examples as a
means of describing some of the problems that are common to
many pharmacogenetic cases. The pharmacogenetic literature
contains many examples of confusing, or even contradictory,
studies that arise due to unknown environmental factors that
result in poor outcomes; drugs whose metabolism/transport are
affected by multiple genes in multiple pathways; and clinically
important genes that have many rare allelic variants with similar phenotypes variation in the frequencies of allelic variants
among ethnic groups that mask the role of any one variant.
These issues are common to most gene/drug dynamics and do not preclude the importance of pharmacogenetic
studies. They do call for more realistic assessments of the
role of genetic testing for the practicing clinician as this field
develops. LM
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